Telomir Pharmaceuticals, Inc.
TELO
$1.26
-$0.03-2.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -68.20% | -92.80% | 471.46% | 66.44% | 201.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.53% | -80.91% | 243.84% | 14.18% | 169.37% |
| Operating Income | 26.53% | 80.91% | -243.84% | -14.18% | -169.37% |
| Income Before Tax | 28.88% | 81.60% | -249.89% | 65.15% | 68.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 28.88% | 81.60% | -249.89% | 65.15% | 68.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.88% | 81.60% | -249.89% | 65.15% | 68.93% |
| EBIT | 26.53% | 80.91% | -243.84% | -14.18% | -169.37% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 37.05% | 83.19% | -245.40% | 67.50% | 71.62% |
| Normalized Basic EPS | 36.99% | 83.16% | -245.10% | 67.47% | -44.10% |
| EPS Diluted | 37.05% | 83.19% | -245.40% | 67.50% | 71.62% |
| Normalized Diluted EPS | 36.99% | 83.16% | -245.10% | 67.47% | -44.10% |
| Average Basic Shares Outstanding | 12.92% | 9.42% | 1.35% | 7.18% | 9.46% |
| Average Diluted Shares Outstanding | 12.92% | 9.42% | 1.35% | 7.18% | 9.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |